10.00

Welcome by Chairs

Solange Peters & Alfredo Addeo

10.05

Advancements in Lung Cancer Diagnostics: Current Guidelines and Emerging Tests

Anne Schultheis (Germany)

10.25

Novel Therapeutic Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

Anne-Marie Dingemans (Netherlands)

10.50

Rare But Actionable: How To Target for RET, METex14 and NTRK

Roberto Ferrara (Italy)

11.10

Open Discussion & Coffee Break

11.30

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

Biagio Ricciuti (USA)

11.50

The Emerging Role of ADCs in Lung Cancer: Navigating Timing and Applications for Optimal Use

Jarushka Naidoo (Ireland)

12.15

Lunch Break

14.00

Surgical Dilemmas in NSCLC: Defining Resectability for Optimal Patient Outcomes in the IO Era

Nuria maria novoa (spain)

14.25

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

Delvys Rodriguez Abreu (Spain)

14.50

Open Discussion & Coffee Break

15.15

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

• We Must Seize Every Opportunity To Cease IO

  Giannis Mountzios (Greece)

• We Must Maximize IO Benefits Through Prolonged Therapy

  Sandip Patel (USA)

15.50

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

Stephen Liu (USA)

16.15

Open Questions, Patient Cases & Guidelines

Panel Discussion With All